Physician profile
Deborah Krause
NPI 1962568550
$2,411.70
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $482 · 2020: $453 · 2021: $647 · 2022: $409 · 2023: $421.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $421.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $420.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $314.82 | 2019-2023 | Rexulti |
| Otsuka America Pharmaceutical, INC. | $307.92 | 2019-2023 | Rexulti, Abilify Maintena |
| Neurocrine Biosciences, INC. | $295.01 | 2019-2023 | Ingrezza |
| Abbvie INC. | $274.26 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $212.04 | 2019-2023 | Spravato, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $179.80 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $145.68 | 2019-2022 | |
| Eisai INC. | $97.59 | 2020-2022 | |
| Alkermes, INC. | $92.06 | 2019-2023 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $79.28 | 2021-2023 | Austedo Xr |
| Allergan, INC. | $67.66 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $64.24 | 2020-2022 | |
| Ironshore Pharmaceuticals INC. | $55.53 | 2019-2020 | |
| Axsome Therapeutics, INC. | $50.74 | 2023 | Auvelity |
| Adlon Therapeutics L.P. | $34.05 | 2020-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $31.24 | 2022-2023 | Azstarys |
| Supernus Pharmaceuticals, INC. | $30.14 | 2022-2023 | Qelbree |
| Jazz Pharmaceuticals INC. | $30.09 | 2021-2022 | |
| Indivior INC. | $25.52 | 2019 | |
| Sunovion Pharmaceuticals INC. | $12.52 | 2020 | |
| Merck Sharp & Dohme LLC | $11.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Krause listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.